This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Seeks More Safety Data on Intrinsa

Updated from 5:21 p.m. EDT

An advisory committee of the Food and Drug Administration said Thursday that an experimental drug to increase women's sexual desire will need more study of its long-term safety before the panel could recommend approval.

The panel voted unanimously that the FDA should reject the product.

The committee of experts said that although the drug Intrinsa, a transdermal patch that transmits the hormone testosterone, is effective, the company's developer hadn't provided enough information about the drug's long-term safety. The drug is made by Procter & Gamble (PG - Get Report), under license from Watson Pharmaceuticals (WPI).

Many Wall Street analysts had speculated that Intrinsa could be the female version of Viagra, the erectile dysfunction drug made by Pfizer (PFE - Get Report).

P&G was asking the advisory committee to approve the drug designed to improve sexual desire in menopausal women whose ovaries have been surgically removed. The FDA isn't bound by its advisory committees' opinions, but the agency usually follows their recommendations.

Intrinsa would be the first FDA-approved drug to treat the condition called hypoactive sexual desire disorder. Other companies are working on female sexual disorder products such as patches, pills, gels, creams and nasal sprays.

The decision is a setback not only to P&G and to Watson but also to a host of other companies that are working on drugs to treat diminished sexual desire in women. The advisory panel's announcement came after markets had closed.

P&G's stock closed up $1.16, or 2.1%, to $55.82 in regular trading. But it gave back 71 cents, or 1.3%, in after-hours trading. Watson's stock closed at $29.30, gaining 23 cents, or 0.8%, in regular trading.

The biggest loser was BioSante Pharmaceuticals (BPA), which is developing a testosterone gel. In regular trading, the company's stock lost 90 cents, or 10.7%, to $7.50. In after-hours trading, the stock was beaten down by $2.50, or 33.3%, to $5.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
WPI $85.73 0.00%
PFE $33.24 0.45%
PG $74.48 0.11%
AAPL $112.12 2.39%
FB $93.24 0.83%


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs